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Abstract 
 
Dementia with Lewy bodies (DLB) is characterized by the accumulation of Lewy 
bodies (LB) and Lewy neurites (LN) in the central nervous system, both of which are 
composed mainly of aggregated α-synuclein phosphorylated at serine 129 (p-α-
synuclein). Although pphosphorylated -α-synuclein is believed to exert toxic effects at 
the synapse in DLB and other α-synucleinopathies, direct evidence for the precise 
synaptic localization has been difficult to achieve due to the lack of adequate optical 
microscopic resoluti n to study human synapses. In the present study we applied array 
tomography, a microscopy technique that combines ultrathin sectioning of tissue with 
immunofluorescence allowing precise identification of small structures, to 
quantitatively investigate the synaptic p-α-synuclein pathology in dementia with Lewy 
bodiesDLB.  
We performed array tomography on human brain samples from the cingulate cortex of 5 
dementia with Lewy bodiesDLB patients, 5 Alzheimer’s disease patients and 5 healthy 
controls to analyse the presence of phosphorylatedp- α-synuclein immunoreactivity at 
the synapse and their relationship with synapse size. Main analyses were performed in 
blocks from cingulate cortex and confirmed in blocks from the striatum of DLB cases. 
A total of 1318700 single pre- or post-synaptic terminals were analysed.   
We found that p-α-synuclein is present exclusively in dementia with Lewy bodiesDLB 
cases, where it can be identified in the form of Lewy bodies, Lewy neurites LN and 
small aggregates (<0.16 µm
3
). 19-25% of phosphorylatedp- α-synuclein deposits were 
found in pre-synaptic terminals mainly in the form of small aggregates. Synaptic 
terminals that co-localized with small aggregates of phosphorylatedp- α-synuclein were 
significantly larger than those that did not. Finally, a gradient of phosphorylatedp- α-
synuclein aggregation in synapses (pre>pre+post>post-synaptic) was observed.   
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These results indicate that phosphorylatedp- α-synuclein is found at the pre-synaptic 
terminals of dementia with Lewy bodiesDLB cases mainly in the form of small 
phosphorylatedp- α-synuclein aggregates that are associated with changes in synaptic 
morphology. Overall, our data support the notion that pathological phosphorylatedp- α-
synuclein may disrupt the structure and function of the synapse in dementia with Lewy 
bodiesDLB.   
 
Keywords: P-α-synuclein, Dementia with Lewy bodies, Synapses, Array Tomography, 
Human tissue. 
 
Abbreviations: DLB, dementia with Lewy bodies; LB, Lewy bodies; LN, Lewy 
neurites;  p-α-synuclein, α-synuclein phosphorylated at serine 129; PSD-95, post-
synaptic density protein 95.. 
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Introduction 
 
Dementia with Lewy bodies (DLB) is the second most common neurodegenerative 
dementia after Alzheimer’s disease (AD). The neuropathological hallmark of DLB is 
the formation of spherical inclusions in the neuronal somata called Lewy bodies (LB) 
and of elongated structures in dendritic or axonal compartments called Lewy neurites 
(LN) in the central and peripheral nervous systems (Goedert et al., 2013).   
In DLB, Lewy bodiesLBs and Lewy neuritesLNs are mainly composed of filaments of 
misfolded α-synuclein protein (Walker et al., 2015). α-synuclein is a synaptic protein 
that is located in pre-synaptic terminals where it contributes to neurotransmission and 
synaptic homeostasis (Maroteaux et al., 1988; Iwai et al., 1995; Clayton and George, 
1999; Lashuel et al., 2013; Burré, 2015; Calo et al., 2016). Under pathological 
conditions α-synuclein is phosphorylated at residue serine 129 (p-α-synuclein). This 
phenomenon occurs constitutively at very low levels, but is markedly enhanced during 
pathological processes in which p-α-synuclein is detected in >90% of α-synuclein 
aggregates (Fujiwara et al., 2002; Hasegawa et al., 2002; Saito et al., 2003; Anderson et 
al., 2006; Muntané et al., 2012). Growing evidence indicates that aggregation of α-
synuclein at synapses is a major event in the pathogenesis of DLB and other α-
synucleinopathies (Calo et al., 2016). In particular, data from transgenic animal models 
suggest a toxic role of α-synuclein in synapses (Garcia-Reitböck et al., 2010; Nemani et 
al., 2010; Lundblad et al., 2012; Calo et al., 2016). In postmortem brains from patients 
with DLB, p-α-synuclein is detected in synaptic-enriched fractions (Muntané et al., 
2008; Walker et al., 2013) and α-synuclein forms small proteinase-k-resistant 
aggregates in pre-synaptic terminals  (Kramer and Schulz-Schaeffer, 2007; Tanji et al., 
2010). These data suggest that, although Lewy bodies B and Lewy neuritesN are the 
classical hallmarks of DLB and other α-synucleinopathies, accumulation of pathological 
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α-synuclein at the synapse may be the main effector of the disease leading to synaptic 
dysfunction and loss. Nonetheless, the study of α-synuclein-mediated synaptic 
pathology in humans has remained elusive, in part because synapses are small structures 
difficult to resolve microscopically in human brain.  
In the present work we applied array tomography, a technique based on the production 
of 70nm consecutive sections combined with immunofluorescence, to image synaptic 
pathology in DLB under the diffraction limit of light (Micheva and Smith, 2007; Kay et 
al., 2013). Array tomography requires special fixation conditions, which limits the 
samples available for this type of studies. This technique has been applied previously to 
successfully demonstrate synaptic abnormalities in animal models of Alzheimer’s 
disease D  and in human Alzheimer’s diseaseD brains (Koffie et al., 2009, 2012; 
Jackson et al., 2016). To our knowledge, this study is the first to use array tomography 
to quantitatively assess synaptic p-α-synuclein in DLB, which allowed us to resolve α-
synuclein pathology in synaptic terminals in human brain samples.    
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Materials and methods 
 
Standard protocol approvals, and patient consents. All brain donors and/or next of 
kin had given written informed consent for the use of brain tissue for research. The 
study was approved by the local ethics committee of: the Hospital de Sant Pau, 
Barcelona, Spain; the Edinburgh Brain Bank ethics committee and the ACCORD 
medical research ethics committee (approval numbers LR/11/ES/0022,  16/ES/0084, 
and 15-HV-016; ACCORD is the Academic and Clinical Central Office for Research 
and Development, a joint office of the University of Edinburgh and NHS Lothian); and 
the Massachusetts Alzheimer’s Disease Research Centre and Massachusetts General 
Hospital Neuropathology department with local Institutional Review Board regulations. 
 
Subjects. Human brain samples were obtained from the Edinburgh Brain Bank -see 
Supplementary Table 1 for Medical Research Council codes-, the Massachusetts 
Alzheimer’s Disease Research Centre and the Neurological Tissue Bank (NTB) of the 
Biobanc-Hospital Clinic-IDIBAPS in Barcelona.  
Brain sampling and processing protocols for neuropathological diagnoses were carried 
out following international recommendations as previously described (Colom-Cadena et 
al., 2013; Kay et al., 2013; Samarasekera et al., 2013). 
Fifteen pPatients fulfilling clinical and neuropathological criteria for DLB (n=5) 
(McKeith et al., 2005), Alzheimer’s diseaseD (n=5) (Montine et al., 2012), or healthy 
control cases (n=5) were included in this study. Clinical and neuropathological data 
were retrospectively obtained from the clinical charts available at the Edinburgh Brain 
Bank, the Massachusetts Alzheimer’s Disease Research Centre and the NTB. 
Neuropathological stages were applied according to international recommendations for 
DLB (McKeith et al., 2005) and, Lewy bodyB pathology (Braak et al., 2003). In cases 
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with concomitant Alzheimer’s diseaseD pathology, current National Institute of 
Ageing/Alzheimer Association guidelines were applied (Montine et al. 2012).    
 
Tissue processing for array tomography. Fresh brain tissue from all cases was 
processed immediately upon collection for array tomography as previously described 
(Micheva and Smith, 2007; Kay et al., 2013). The processing was the same for all cases 
regardless of the collection centre. Briefly, 1mm x 1mm x 3mm tissue blocks from the 
cingulate cortex comprising all cortical layers and the striatum (nucleus putamen) were 
sectioned. Tissue blocks were fixed in 4% paraformaldehyde and 2.5% sucrose in 
20mM phosphate buffered saline pH 7.4 (PBS) for up to 3 hours. Samples were 
dehydrated through ascending concentrations of ethanol, embedded into LR White 
acrylic resin (Electron Microscopy SciencesEMS) and introduced into gelatine capsules 
where resin was allowed to polymerize overnight at >50ºC. After polymerization, tissue 
blocks were stored at room temperatureRT until used. 
 
70nm-array production. LR white embedded tissue blocks were cut at 70nm sections 
using an ultramicrotome (Leica) equipped with an Ultra Jumbo Diamond Knife 35º 
(Diatome). Ribbons of at least 30 consecutive sections were produced and collected in 
gelatine subbed coverslips. For each case, two adjacent blocks of the cingulate cortex 
were processed as described below (see Fig. 1 for study design). 
 
Immunofluorescence. Coverslips with 70nm consecutive sections were stained as 
previously described (Kay et al., 2013). Sections were incubated with Tris-Glycine 
solution 5’ at room temperatureRT followed by a blocking of unspecific antigens with a 
cold water fish blocking buffer (Sigma-Aldrich) for 30 min. Sections were then 
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incubated for 2 hours with the following primary antibodies: mouse anti-α-synuclein 
phosphorylated at serine 129 (dilution 1:50, clone P-α-synuclein #64, WAKO), goat 
anti-synaptophysin (dilution 1:50, AF5555, R&D Systems) and rabbit anti- post-
synaptic density protein 95 ( PSD-95) (dilution 1:50, clone D27E11, Cell Signaling), 
rabbit anti synapsin I (dilution 1:50, AB1543P, Millipore) or rabbit anti- α-synuclein 
(dilution 1:50, AB5038, Millipore). After Tris buffered salineTBS washings, secondary 
fluorescent antibodies Alexa 488, Alexa 555 and Alexa 647 (dilution 1:50, Invitrogen) 
were applied for 30’. Sections were washed with Tris buffered salineTBS and samples 
were stained with Hoechst 33258 (dilution 1:100, Life Technologies) for 5 min for 
nuclei visualization. Finally, coverslips were mounted on microscope slides with Immu-
Mount (Fisher Scientific) mounting media.    
 
Image acquisition. Images of the same region were acquired in consecutive sections 
using an Olympus BX61 microscope equipped with: 454, 488, 555 and 647 single-band 
pass filters (49000, 49002, 49004 and 49009 respectively, Chroma); an Orca Flash 4.0 
LT camera (Hamamatsu); and a 64x 1.2NA Plan Apochromat objective (Olympus) 
controlled with HCImage software (Hamamatsu). For Stimulated Emission Depletion 
microscopy, images from one representative DLB case were acquired using a TCS 5 
Stimulated Emission Depletion CW microscope (Leica Microsystems). The CW 
Stimulated Emission Depletion laser operates at the wavelength of 592 nm and imaging 
is performed using hybrid detectors. The system performance has been fully 
characterized and a complete analysis of the achieved transversal resolution can be 
found elsewhere (Merino et al., 2017). Sections with omission of antibodies or with 
secondary antibodies only were imaged to ensure specific and independent fluorophore 
visualization. For co-localization purposes, images were acquired avoiding saturated 
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pixels. Saturation was only minimally applied for figure visualization. For each case, 
three fields of each section were imaged comprising all cortical layers (see Fig. 1 for 
details). 
 
Image processing and analysis.  Image stacks of each channel comprising all 70nm 
consecutive sections were first registered as previously described (Kay et al., 2013b) 
using Multistackreg 1.4 ImageJ plugin (courtesy of Brad Busse based on (Thévenaz et 
al., 1998), based on a rigid registration followed by an affine registration of a reference 
channel that is applied to the other channels.  
After alignment, identification of immunofluorescent objects and quantification of 
overlapping objects was achieved using an in-house semi-automatic algorithm (see Fig. 
1 for details). Aligned sections were segmented using an automated local thresholding. 
Additionally, objects that were not in at least two consecutive sections were considered 
background and removed. Segmentation parameters were exclusive for each channel, 
but were the same for all included cases. A total of 13187001023248 single pre- or post-
synaptic terminals were identified. 
After identification of three-dimensional objects, three different analyses were 
performed: 1) the density of objects for each channel subtracting the area occupied by 
cell bodies and/or blood vessels using a mask of the maximum intensity projection of 
the synaptophysin channel; 2) the proportion of channel objects that overlap with 
objects from another channel; and 3) the median size of all objects and of those co-
localizing (see Fig. 1 for details). The in-house semi-automatic algorithm can be freely 
accessed at https://github.com/MemoryUnitSantPau.  
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Experimental design. The immunostaining, image acquisition, and image processing 
and analyses were carried out blinded to the clinicopathological diagnosis by assigning 
a random code to each sample.  
 
Statistical analysis. Kruskal-Wallis with uncorrected Dunn’s analysis post-hoc tests 
were used to compare differences between three groups in p-α-synuclein densities, co-
localization percentages or object sizes. Statistical significance was set at 5% (α= 0.05). 
All data were analysed using the Statistical Package for the Social Sciences version 19.0 
(SPSS Inc., Chicago, IL, USA).  
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Results 
 
Demographic, clinical and neuropathologic characteristics of cases 
Demographic, clinical and neuropathologic data are shown in Table 1. As expected, the 
DLB group exhibited advanced α-synuclein pathology as assessed by McKeith types 
and Lewy bodyB Braak stages. A group of healthy subjects and Alzheimer’s diseaseD 
cases were included as controls for the AT array tomography analyses.  
 
P-α-synuclein is located in DLB pre-synaptic terminals 
P-α-synuclein immunoreactivity in DLB was detected in array tomography in the form 
of Lewy bodiesB, Lewy neuritesN as well as small aggregates, the latter being defined 
as objects <0.16µm
3
 without a clear dendritic or axonal morphology (Fig. 2A-B). 
Occasionally, p-α-synuclein immunoreactivity in cell nuclei was also observed. 
Quantification of total p-α-synuclein aggregates confirmed that pathology was restricted 
to DLB in this area array tomography, with negligible levels in Alzheimer’s diseaseD 
and controls (Fig. 2C). In contrast, immunoflurorescence for non-phosphorylated α-
synuclein showed a diffuse punctate pattern in grey matter in both controls and DLB. 
There was a high degree of overlap between p-α-synuclein and non-phosphorylated α-
synuclein in DLB aggregates (Supplementary Fig. 1). Therefore we chose p-α-
synuclein as a marker to investigate the synaptic pathology in DLB.  
We found that 19.17±4.4% of p-α-synuclein aggregates co-localized with 
synaptophysin-positive terminals in the cingulate cortex (Fig. 2D, Supplementary Fig. 
12, Supplementary Mov. 1). These data were consistent across cases and revealed that 
most of the p-α-synuclein present at the pre-synapse consisted of small aggregates 
(76.6±4%), while medium-sized aggregates or Lewy neuritesN were less abundant 
(23.4±4%). As expected, no co-localization was found between Lewy bodiesB and 
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synaptic terminals. Of the total synaptophysin-positive synaptic terminals analysed in 
DLB cases (n= 252696), 2.7±1% contained p-α-synuclein. 
 
The pre-synaptic localization of p-α-synuclein aggregates was confirmed using synapsin 
I as an additional pre-synaptic marker. We found that 25.9±7.3% of p-α-synuclein 
aggregates co-localized with synapsin I-positive terminals (Supplementary Fig. 3). As 
expected, most synapsin I-positive terminals co-localized with synaptophysin.  
We used the striatum (putamen) as an additional region to confirm these findings. We 
found that 19.68±12.7% of p-α-synuclein aggregates in the putamen were co-localizing 
with synaptophysin-positive pre-synaptic terminals.   
 
Pre-synaptic terminal size and p-α-synuclein aggregation 
Synaptic terminals that co-localized with small aggregates of p-α-synuclein were 
1.43±0.17-fold larger than those that did not (p=0.014, Fig. 3). Interestingly, this 
difference was not observed when comparing the size of synaptophysin terminals 
without p-α-synuclein with those that co-localized with LNs. 
 
Trans-synaptic localization of p-α-synuclein 
Trans-synaptic propagation of p-α-synuclein pathology has been proposed as a common 
mechanism in synucleinopathies (Recasens and Dehay, 2014). To investigate this 
phenomenon in vivo, we next selected those synaptophysin pre-synaptic terminals that 
were opposed to objects labelled with the post-synaptic terminal marker PSD-95 (Fig. 
4A). In those paired terminals we observed that p-α-synuclein was more frequently 
located in pre-synaptic terminals (49.82±4.3%, Fig. 4B), followed by a both pre- and 
post-synaptic localization (33.99±2.4%) and less frequently in the post-synaptic density 
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only (16.18±3%). The synaptic gradient of p-α-synuclein was also observed in the 
striatum, with a more pronounced pre-synaptic predominance (70.14±11.2% pre-
synaptic-only, 23.13±13.7% pre- and post-synaptic, 6.73±5.2% post-synaptic only). The 
post-synaptic terminal localization of p-α-synuclein was also confirmed by using 
Stimulated Emission Depletion microscopy in order to increase the lateral resolution 
(Fig. 4C). These data confirm that although p-α-synuclein aggregates are preferentially 
located at the pre-synapse, they can be independently found at the post-synapse as well.   
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Discussion 
 
In the present study we have shown by array tomography that aggregates of p-α-
synuclein were present at the synapse in DLB cases. In pre-synaptic terminals, the 
majority of p-α-synuclein was found in the form of small aggregates, while other types 
of aggregates, like Lewy bodiesB or Lewy neuritesN, are less abundant. Moreover, 
these small aggregates were associated with structural changes in pre-synaptic 
terminals. Finally, we observed a gradient of p-α-synuclein aggregates from the pre- to 
post-synaptic compartments.  
There is growing evidence that synaptic abnormalities in DLB precede neuronal loss 
and Lewy bodiesB formation (Chung et al., 2009; Nikolaus et al., 2009; Calo et al., 
2016; Henstridge et al., 2016) and that these synaptic defects may beare closely related 
with clinical symptoms (Vallortigara et al., 2014; Whitfield et al., 2014; Bereczki et al., 
2016). However, the investigation of DLB as a primary synaptopathy has been 
hampered by our technical ability to study synapses in human brain. The small size of 
synaptic terminals falls under the diffraction limit of light, which limits the use of 
conventional optical microscopy techniques for this purpose. Electron microscopy, 
which has been the standard technique to resolve the structure of synapses, only permits 
the reconstruction of small brain volumes and is less amenable to labelling multiple 
proteins (O’Rourke et al., 2012).  
In the present work we applied array tomography to image synaptic pathology in DLB 
under the diffraction limit of light (Micheva and Smith, 2007; Kay et al., 2013). To our 
knowledge, this is the first study to apply array tomography in DLB brains, a technique 
that has allowed us to perform large-scale quantitative synaptic imaging. We analysed 
13187001023248 single pre- or post-synaptic terminals together with p-α-synuclein 
with very high spatial resolution. Previous studies have investigated synaptic proteins in 
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DLB brains using conventional immunohistochemistry (Wakabayashi et al., 1994; 
Revuelta et al., 2008; Scott et al., 2010) or biochemical analysis of brain homogenates 
(Masliah et al., 1993; Brown et al., 1998; Hansen et al., 1998; Campbell et al., 2000; 
Reid et al., 2000; Kramer and Schulz-Schaeffer, 2007; Mukaetova-Ladinska et al., 
2013; Khundakar et al., 2016; Xing et al., 2016). In some of these studies, p-α-
synuclein and proteinase-k resistant α-synuclein aggregates were found in synaptic-
enriched fractions (Kramer and Schulz-Schaeffer, 2007; Muntané et al., 2008; Tanji et 
al., 2010; Walker et al., 2013). However, many of these studies could not specifically 
address the precise synaptic localization due to the low resolution of the techniques 
used. Our results confirm and expand on these observations in intact brain samples by 
using a technique especially suited for the analysis of human brain synapses. 
 
We found that ~20% of p-α-synuclein aggregates were colocalizing with 
synaptophysin-positive terminals in the cingulate cortex and striatum. The percentage 
was a slightly higher (25%) when using synapsin I as a presynaptic marker. The 
detection of p-α-synuclein at pre-synaptic compartments suggests a role in synaptic 
degeneration. Notably, we found that small α-synuclein aggregates are the most 
common form in synapses. A previous study (Kramer and Schulz-Schaeffer, 2007) 
described proteinase-k-resistant aggregates in pre-synaptic compartments that 
represented the 50-90% of α-synuclein aggregates. We found a much lower percentage 
of α-synuclein aggregates at the pre-synaptic terminals. This difference may be due to 
numerous methodological differences: the antibodies used; the methods to detect 
synapses and pathological aggregates; or our stringent protocol used to define p-α-
synuclein and synaptophysin-containingpresynaptic objects. Despite these 
methodological issues, we found that 77% of p-α-synuclein aggregates in contact with 
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pre-synaptic terminals are small aggregates. Taken together, both studies support the 
notion of small α-synuclein aggregates as key pathological forms in driving synaptic 
damage and dysfunction (Schulz-Schaeffer, 2010).  
 
Our results are also in line with the hypothesis that the pre-synaptic terminal is an early 
site of α-synuclein aggregation in DLB and other α-synucleinopathies, the same site 
where it is found under physiological conditions (Lashuel et al., 2013; Spinelli et al., 
2014; Volpicelli-Daley et al., 2014; Majd et al., 2015; Abeliovich and Gitler, 2016). 
The aggregation of α-synuclein may lead to abnormal functional impairment of 
neurotransmitter release (Garcia-Reitböck et al., 2010; Nemani et al., 2010), subsequent 
to axonal transport defects through the impairment of endosome and/or autophagosome 
transport (Volpicelli-Daley et al., 2014), which may lead to neurodegeneration (Ferrer 
et al., 2001; Desplats et al., 2009; Decressac et al., 2013).    
We also observed larger pre-synaptic terminal volume in the presence of p-α-synuclein. 
Interestingly, an inverse correlation has been observed between synaptic density and the 
size of remaining synapses in Alzheimer’s diseaseD as measured by the length of the 
post-synaptic density (DeKosky and Scheff, 1990; Scheff et al., 1990; Scheff and Price, 
1993). This enlargement of remaining synapses has been interpreted as a compensatory 
response, rather than as selective loss of small synapses. Our data could suggest a 
similar compensatory mechanism in synapses containing pathological p-α-synuclein.   
Several previous studies in cellular and animal models have shown that α-synuclein 
may propagate along neural circuits following a hierarchical pattern (Eisbach and 
Outeiro, 2013; Masuda-Suzukake et al., 2013; Recasens and Dehay, 2014). The 
observation of a spatial gradient in p-α-synuclein aggregation in synapses 
(pre>pre+post>post-synaptic) could be interpreted as a sign of trans-synaptic spreading 
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of α-synuclein pathology. However, using Stimulated Emission Depletion microscopy 
we found that although p-α-synuclein predominates at the pre-synapse it can also be 
found independently at the post-synapse. Due to the inherent descriptive nature of post-
mortem studies and the difficulties to identify the synaptic cleft, additional research is 
needed to elucidate if our findings are related to α-synuclein spreading and/or 
independent aggregation in both synaptic compartments. another possible explanation 
for this observation may be the limited resolution of the technique to clearly dissociate 
the pre- and post-synapse. 
 
Despite the limitations of our study -–relatively small sample size, analysis of a single 
brain regioninclusion of cases with advanced disease stages, or analysis of a single 
phospho-epitope of p-α-synuclein-, our findings are important as they demonstrate for 
the first time that p-α-synuclein accumulates in pre-synaptic terminals by large-scale 
imaging of synapses in DLB brain. Taken together, the present work provides a visual 
and quantitative evidence of the synaptic deposition of small p-α-synuclein aggregates 
in pre-synaptic terminals. This study supports the hypothesis that DLB and other α-
synucleinopathies are primary synaptopathies. These data should stimulate the search 
for therapies aimed at reducing synaptic α-synuclein-induced damage or spread.         
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Figure legends 
 
Figure 1. Study design.  
Tissue collection and processing of each case is shown in A. For each case, two 
adjacent tissue sections of cingulate cortex or the striatum (putamen nucleus) were 
processed and embedded in LR white. For each block a ribbon of >40 consecutive 
sections of 70nm was produced. Each ribbon was immunostained for synaptophysin 
(red), p-α-synuclein (green) and PSD-95 (cyan), synapsin I or α-synuclein, and nuclei 
were visualized with Hoescht 33258 (blue). Three subregions of cortex were imaged 
through the entire ribbon. In B and C, the processing and analysis of the images is 
summarized. 1. First, individual channel stacks were produced, with all consecutive 
sections imaged. Consecutive sections of a reference channel (i.e. synaptophysin) were 
registered using a rigid and an affine transformation. Transformation matrices were 
applied to other channels. 2. Second, images were segmented using an in-house 
algorithm based on local mean threshold segmentation, removing single section objects, 
filtering by size, and detecting three dimensional3D objects as 6 neighbour connected 
components. Raw images (right) and segmented (left) representative images are shown. 
Each image corresponds to a single 70nm section with its corresponding orthogonal 
views. 3. Neuropil area was calculated based on a maximum intensity projection of 
synaptophysin channel. 4. Co-localization between the channels of interest and the sizes 
of co-localizing objects was calculated 5. The object density and object size were 
quantified and 6. For entire synaptic studies, segmented images of synaptophysin (pre-
synaptic) and PSD-95 (post-synaptic) channels combined to remove all those objects 
without pre- and post-synaptic pairs. Abbreviations: Max Int, Maximum intensity;. 6n, 
six neighbour.  Scale bar in A and B, 10µm; in C, 2µm. 
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Figure 2. P-α-synuclein immunoreactivity patterns and synaptic localization. 
A Representative images of DLB, control and Alzheimer’s disease cases stained with 
antibodies against synaptophysin (red) and p-α-synuclein (green). Each image is a 
maximum intensity projection of 31 consecutive sections. B Representative three 
dimensional3D representations of types of p-α-synuclein aggregates (green) found in 
DLB cases (green) and synaptophysin terminals (red). Lewy bodies did not co-localize 
with synaptophysin terminals, while Lewy neurites and small aggregates did 
(arrowheads). C The quantification of total p-α-synuclein objects revealed that 
pathology was found almost exclusively in DLB cases (**, p<0.01). D Synaptograms 
representing six 70nm consecutive sections (from left to right and top to bottom) of the 
Lewy neurite (LN) or small aggregate (SA) pointed by the arrowheads in B. Are 
represented bBoth the raw and segmented images are shown. At right, tThe percentage s 
of pre-synaptic p-α-synuclein found of LN or SA that are pre-synaptic and the 
percentage ofand extra-synaptic p-α-synuclein are indicated. Abbreviations: DLB, 
dementia with Lewy bodies; AD, Alzheimer disease; LN, Lewy neurite; SA, Small 
aggregate. Scale bar in A, 10µm; in B, 2µm; in D, 1µm. 
 
Figure 3. Median volume of pre-synaptic terminals co-localizing with p-α-synuclein. 
A Three dimensional reconstruction of 20 consecutive sections from a DLB case is 
shown. P-α-synuclein (green) and synaptophysin (red) are shown. Black arrowheads 
indicate synaptophysin objects that co-localize with small aggregates of p-α-synuclein, 
grey arrowheads points to synaptic terminals that co-localize with Lewy neurites, and 
white arrowheads those synaptophysin objects that do not co-localize with p-α-
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synuclein. B Median volumes of synaptic terminals according to co-localization with p-
α-synuclein (p-α-synuclein +, or -) and their characteristic pattern (small aggregate or 
Lewy neurite). Abbreviations: Psyn: Phosphorylated-α-synuclein; SA, small aggregate; 
LN, Lewy neurite. Scale bar in A, 2µm. 
 
Figure 4. Trans-synaptic localization of p-α-synuclein. 
A Three dimensional reconstruction of 20 consecutive sections from a DLB case. P-α-
synuclein (green), synaptophysin (red) and PSD-95 (blue) are shown. White arrowheads 
point to zones where p-α-synuclein co-localizes with synaptophysin (pre-synaptic), 
PSD-95 (post-synaptic) or both (pre and post-synaptic). In B, p-α-synuclein objects that 
co-localized with synaptic pairs (synaptophysin and PSD-95 objects) are classified 
depending on its pre-synaptic, pre and post-synaptic or post-synaptic localization. The 
relative co-localization of p-α-synuclein with the synaptophysin pre-synaptic marker 
was significantly higher than the PSD-95 post-synaptic co-localization. C A 
representative reconstruction of synaptic pairs from twenty 70 nm sections from a DLB 
case. Synaptophysin is shown in red and PSD-95 in cyan. The black square on the left 
image represents the inset magnified on the right image. At the bottom a synaptogram 
of ten 70nm consecutive sections is shown. Representative images of the colocalization 
between between p-α-synuclein, synaptophysin and PSD-95 using  array tomography 
combined with Stimulated Emission Depletion microscopy. A single 70nm-thick 
section stained for p-α-synuclein (green), synaptophysin (red) and PSD-95 (blue) is 
shown. Stimulated Emission Depletion was applied to image PSD-95 (upper row) or p-
α-synuclein (lower row).  Abbreviations: STED, Stimulated Emission Depletion. Scale 
bar in A, 2µm; in C, 1µm. 
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Figure 1. Study design.  
Tissue collection and processing of each case is shown in A. For each case, two adjacent tissue sections of 
cingulate cortex or the striatum (putamen nucleus) were processed and embedded in LR white. For each 
block a ribbon of >40 consecutive sections of 70nm was produced. Each ribbon was immunostained for 
synaptophysin (red), p-α-synuclein (green) and PSD-95 (cyan), synapsin I or α-synuclein, and nuclei were 
visualized with Hoescht 33258 (blue). Three subregions were imaged through the entire ribbon. In B and C, 
the processing and analysis of the images is summarized. 1. First, individual channel stacks were produced, 
with all consecutive sections imaged. Consecutive sections of a reference channel (i.e. synaptophysin) were 
registered using a rigid and an affine transformation. Transformation matrices were applied to other 
channels. 2. Second, images were segmented using an in-house algorithm based on local mean threshold 
segmentation, removing single section objects, filtering by size, and detecting three dimensional objects as 
6 neighbour connected components. Raw images (right) and segmented (left) representative images are 
shown. Each image corresponds to a single 70nm section with its corresponding orthogonal views. 3. 
Neuropil area was calculated based on a maximum intensity projection of synaptophysin channel. 4. Co-
localization between the channels of interest and the sizes of co-localizing objects was calculated 5. The 
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object density and object size were quantified and 6. For entire synaptic studies, segmented images of 
synaptophysin (pre-synaptic) and PSD-95 (post-synaptic) channels combined to remove all those objects 
without pre- and post-synaptic pairs. Abbreviations: Max Int, Maximum intensity; 6n, six neighbour.  Scale 
bar in A and B, 10µm; in C, 2µm.  
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Figure 2. P-α-synuclein immunoreactivity patterns and synaptic localization. 
A Representative images of DLB, control and Alzheimer’s disease cases stained with antibodies against 
synaptophysin (red) and p-α-synuclein (green). Each image is a maximum intensity projection of 31 
consecutive sections. B Representative three dimensional representations of types of p-α-synuclein 
aggregates (green) found in DLB cases and synaptophysin terminals (red). Lewy bodies did not co-localize 
with synaptophysin terminals, while Lewy neurites and small aggregates did (arrowheads). C The 
quantification of total p-α-synuclein objects revealed that pathology was found almost exclusively in DLB 
cases (**, p<0.01). D Synaptograms representing six 70nm consecutive sections (from left to right) of the 
Lewy neurite (LN) or small aggregate (SA) pointed by the arrowheads in B. Both the raw and segmented 
images are shown. The percentage s of pre-synaptic p-α-synuclein found of LN or SA and extra-synaptic p-
α-synuclein are indicated. Abbreviations: DLB, dementia with Lewy bodies; AD, Alzheimer disease; LN, Lewy 
neurite; SA, Small aggregate. Scale bar in A, 10µm; in B, 2µm; in D, 1µm.  
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Figure 3. Median volume of pre-synaptic terminals co-localizing with p-α-synuclein.  
A Three dimensional reconstruction of 20 consecutive sections from a DLB case is shown. P-α-synuclein 
(green) and synaptophysin (red) are shown. Black arrowheads indicate synaptophysin objects that co-
localize with small aggregates of p-α-synuclein, grey arrowheads point to synaptic terminals that co-localize 
with Lewy neurites, and white arrowheads those synaptophysin objects that do not co-localize with p-α-
synuclein. B Median volumes of synaptic terminals according to co-localization with p-α-synuclein (p-α-
synuclein +, or -) and their characteristic pattern (small aggregate or Lewy neurite). Abbreviations: Psyn: 
Phosphorylated-α-synuclein; SA, small aggregate; LN, Lewy neurite. Scale bar in A, 2µm.  
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Figure 4. Trans-synaptic localization of p-α-synuclein.  
A Three dimensional reconstruction of 20 consecutive sections from a DLB case. P-α-synuclein (green), 
synaptophysin (red) and PSD-95 (blue) are shown. White arrowheads point to zones where p-α-synuclein 
co-localizes with synaptophysin (pre-synaptic), PSD-95 (post-synaptic) or both (pre and post-synaptic). In 
B, p-α-synuclein objects that co-localized with synaptic pairs (synaptophysin and PSD-95 objects) are 
classified depending on its pre-synaptic, pre and post-synaptic or post-synaptic localization. The relative co-
localization of p-α-synuclein with the synaptophysin pre-synaptic marker was significantly higher than the 
PSD-95 post-synaptic co-localization. C Representative images of the colocalization between between p-α-
synuclein, synaptophysin and PSD-95 using array tomography combined with Stimulated Emission Depletion 
microscopy. A single 70nm-thick section stained for p-α-synuclein (green), synaptophysin (red) and PSD-95 
(blue) is shown. Stimulated Emission Depletion was applied to image PSD-95 (upper row) or p-α-synuclein 
(lower row).  Abbreviations: STED, Stimulated Emission Depletion. Scale bar in A, 2µm; in C, 1µm.  
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Table 1. Demographic, clinical and neuropathologic data of control, DLB and AD 
Alzheimer’s disease cases. 
Case Diagnosis Gender 
Age 
at 
death 
PMI 
(h) 
McKeith 
type 
LB 
Braak 
stage 
Braak 
NFT 
stage 
1 Control M 82 24 - 0 0 
2 Control M 63 16 - 0 0 
3 Control F 77 75  - 0 I 
4 Control M 78  39 - 0 I 
5 Control F 83 8 - 0 II 
6 DLB M 71 8 Neocortical 5 III 
7 DLB M 83 24 Neocortical 5 IV 
8 DLB F 62 9 Neocortical 5 IV 
9 DLB M 77 36 Neocortical 5 III 
10 DLB F 83 24 Neocortical 6 VI 
11 AD M 81  74 - 0 V 
12 AD M 72  109 - 0  VI 
13 AD M 81  83 - 0 VI 
14 AD M 85  91 - 0 VI 
15 AD F 90 18 - 0 V 
Abbreviations: PMI, Post-mortem interval; h, hours; LB, Lewy body; NFT, Neurofibrillary tangle; DLB, 
dementia with Lewy bodies; AD, Alzheimer disease. 
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Supplementary Table 1. The Medical Research Council (MRC) Edinburgh Brain & 
Tissue Bank cases. 
 
Case 
BNN 
Number 
SD063/13 19686 
SD024/15 26495 
SD056/14 24527 
SD005/16 28410 
SD010/16 28771 
MRC numbers and associated BNN numbers. 
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Supplementary Figure 1. Distribution of non-phosphorylated and phosphorylated α-
synuclein in dementia with Lewy bodies and controls. 
 
A Representative images of brain sections of a case with dementia with Lewy bodies and a control case 
stained with antibodies against non-phosphorylated α-synuclein (red) and p-α-synuclein (green). Each 
image is a maximum intensity projection of 20 consecutive sections. B Three dimensional representation 
of non-phosphorylated alpha-synuclein (red) and p-α-synuclein (green) aggregates found in DLB cases. 
An inset of the low magnification image is shown on the right. Abbreviations: DLB, dementia with Lewy 
bodies. Scale bar in A, 10µm; in B, 5µm (left) and 2µm (right). 
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Supplementary Figure 2. Segmentation and co-localization examples. 
 
A Three dimensional representations of the images shown in Figure 2 as well as synaptograms 
representing six 70nm consecutive sections (from left to right and top to bottom) of a Lewy neurite (LN) 
or a small aggregate (SA) (green) colocalizing with synaptophysin (red) pointed by the arrowheads. Both 
the raw and segmented images are shown. B 3D examples of other segmented Lewy neurites and small 
aggregates. Synaptograms on the bottom-right represent a magnification of the pointed area. 
Abbreviations: LN, Lewy neurite; SA, Small aggregate. Scale bars in A and B, 2µm. 
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Supplementary Figure 3. Pre-synaptic localization of p-α-synuclein and synapsin I in 
DLB.  
 
A Three dimensional reconstruction of 20 consecutive sections from a DLB case. P-α-synuclein (green), 
synaptophysin (red) and synapsin I (blue) are shown. An inset of the low magnification image is shown 
on the right. Arrowheads indicate objects with co-localization of all three markers. Scale bars 10µm (left) 
and 2µm (right). 
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